Asaf Danziger Sells 7,383 Shares of NovoCure Limited (NASDAQ:NVCR) Stock

NovoCure Limited (NASDAQ:NVCR) CEO Asaf Danziger sold 7,383 shares of the firm’s stock in a transaction dated Tuesday, July 11th. The stock was sold at an average price of $19.95, for a total value of $147,290.85. Following the transaction, the chief executive officer now owns 462,765 shares of the company’s stock, valued at $9,232,161.75. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Asaf Danziger also recently made the following trade(s):

  • On Monday, July 10th, Asaf Danziger sold 274,359 shares of NovoCure Limited stock. The stock was sold at an average price of $18.07, for a total value of $4,957,667.13.
  • On Wednesday, July 5th, Asaf Danziger sold 155,088 shares of NovoCure Limited stock. The stock was sold at an average price of $18.14, for a total value of $2,813,296.32.
  • On Thursday, July 6th, Asaf Danziger sold 160,138 shares of NovoCure Limited stock. The stock was sold at an average price of $18.14, for a total value of $2,904,903.32.
  • On Monday, June 19th, Asaf Danziger sold 124,720 shares of NovoCure Limited stock. The stock was sold at an average price of $15.51, for a total value of $1,934,407.20.
  • On Friday, June 16th, Asaf Danziger sold 42,457 shares of NovoCure Limited stock. The shares were sold at an average price of $15.15, for a total value of $643,223.55.
  • On Wednesday, June 14th, Asaf Danziger sold 94,102 shares of NovoCure Limited stock. The shares were sold at an average price of $15.22, for a total value of $1,432,232.44.
  • On Monday, June 12th, Asaf Danziger sold 180,601 shares of NovoCure Limited stock. The shares were sold at an average price of $15.13, for a total value of $2,732,493.13.

Shares of NovoCure Limited (NASDAQ:NVCR) opened at 19.10 on Wednesday. The company’s market capitalization is $1.70 billion. The company’s 50 day moving average price is $18.29 and its 200-day moving average price is $11.76. NovoCure Limited has a 1-year low of $5.95 and a 1-year high of $21.75.

NovoCure Limited (NASDAQ:NVCR) last released its quarterly earnings data on Thursday, July 27th. The medical equipment provider reported ($0.24) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.23) by $0.01. The business had revenue of $38.38 million during the quarter, compared to analyst estimates of $42.20 million. NovoCure Limited had a negative net margin of 75.91% and a negative return on equity of 69.48%. On average, equities analysts forecast that NovoCure Limited will post ($0.75) earnings per share for the current year.

WARNING: This article was first published by BBNS and is the property of of BBNS. If you are accessing this article on another website, it was illegally copied and reposted in violation of U.S. and international trademark & copyright legislation. The correct version of this article can be viewed at https://baseballnewssource.com/markets/novocure-limited-nasdaqnvcr-ceo-asaf-danziger-sells-7383-shares-updated-updated-updated/1196857.html.

Several hedge funds have recently made changes to their positions in the company. Bank of Montreal Can increased its stake in shares of NovoCure Limited by 1,919.7% in the second quarter. Bank of Montreal Can now owns 7,069 shares of the medical equipment provider’s stock worth $122,000 after buying an additional 6,719 shares in the last quarter. BNP Paribas Arbitrage SA increased its stake in shares of NovoCure Limited by 792.5% in the second quarter. BNP Paribas Arbitrage SA now owns 7,229 shares of the medical equipment provider’s stock worth $125,000 after buying an additional 6,419 shares in the last quarter. Nisa Investment Advisors LLC purchased a new stake in shares of NovoCure Limited during the second quarter worth about $126,000. Fox Run Management L.L.C. purchased a new stake in shares of NovoCure Limited during the second quarter worth about $225,000. Finally, Legal & General Group Plc increased its stake in shares of NovoCure Limited by 8.5% in the second quarter. Legal & General Group Plc now owns 13,866 shares of the medical equipment provider’s stock worth $238,000 after buying an additional 1,092 shares in the last quarter. Institutional investors and hedge funds own 24.96% of the company’s stock.

NVCR has been the topic of several analyst reports. Zacks Investment Research raised NovoCure Limited from a “sell” rating to a “buy” rating and set a $19.00 target price on the stock in a research report on Thursday, June 29th. J P Morgan Chase & Co reaffirmed a “buy” rating and set a $14.00 target price on shares of NovoCure Limited in a research report on Monday, May 1st. ValuEngine raised NovoCure Limited from a “sell” rating to a “hold” rating in a research report on Saturday, June 3rd. BidaskClub cut NovoCure Limited from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, July 19th. Finally, Aegis reissued a “buy” rating and issued a $14.00 price objective on shares of NovoCure Limited in a research report on Tuesday, April 18th. Three investment analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $19.29.

NovoCure Limited Company Profile

NovoCure Limited is a commercial-stage oncology company. The Company is engaged in developing a cancer treatment centered on a therapy called TTFields, the use of electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Its TTFields delivery system is used for the treatment of glioblastoma (GBM) and to advance programs testing of TTFields in multiple solid tumor indications through its clinical pipeline.

Insider Buying and Selling by Quarter for NovoCure Limited (NASDAQ:NVCR)

Receive News & Ratings for NovoCure Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovoCure Limited and related companies with our FREE daily email newsletter.

 


Latest News

Kris Bryant Back in Spotlight, Cubs Pushing for Playoff Berth
Kris Bryant Back in Spotlight, Cubs Pushing for Playoff Berth
Despite Changes to Reduce The Length of Games, MLB Games are Actually Getting Longer
Despite Changes to Reduce The Length of Games, MLB Games are Actually Getting Longer
Despite Hitting Home Run, Judge Sets Longest Game Streak for Strikeouts
Despite Hitting Home Run, Judge Sets Longest Game Streak for Strikeouts
Los Angeles Dodgers Move 50 Games Over .500
Los Angeles Dodgers Move 50 Games Over .500
Miami’s Giancarlo Stanton Sets Marlins Home Run Record
Miami’s Giancarlo Stanton Sets Marlins Home Run Record
Bryce Harper Latest Star to Suffer Injury
Bryce Harper Latest Star to Suffer Injury


Leave a Reply

 
© 2006-2017 BBNS.